Recent Updates
Recently added Catalysts

GB2064

Phase 2

Myelofibrosis | Small molecule | Oncology |Galecto, Inc.|Last Updated: Apr 3, 2024

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLEDDMC
Total Trials1
Total Enrollment21
FDA Designations
No designations recorded
Clinical trial landscape

GB2064 · 1 trial · 1 indication

Phase 2 1
NCT04679870A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With MyelofibrosisMyelofibrosis
ACTIVE NOT_RECRUITING21 Analytics
PHASE2ACTIVE NOT_RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis
Myelofibrosis
NCT0467987021
Unlock trial analytics
Study Endpoints
Primary Endpoints
Safety and tolerability of GB2064: AE
9 Months

Incidence and severity of adverse events as reported by investigators

Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
GB2064EXPERIMENTALGB2064 will be administered orally as 4 x 250 mg tablets twice a day.
Interventions
NameTypeDescription
GB2064DRUGGB2064 (formerly PAT-1251) is a high-affinity, selective, mechanism-based, small molecule inhibitor of LOXL2, administered twice a day
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites11

Inclusion Criteria: Participants must satisfy all of the following criteria at the Screening visit: 1. Adult male or female participants ≥ 18 years of age at enrolment: 1. Female participants may be of non-childbearing potential defined as permanently sterile or postmenopausal, or female parti...

Countries:United StatesAustraliaGermanyItaly
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT04679870primaryCompletionDate: changed
LOWMay 24, 2026NCT04679870studyFirstPostDate: changed